DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,623,335 B2 Waddington (45) Date of Patent: Jan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,623,335 B2 Waddington (45) Date of Patent: Jan USOO8623335B2 (12) United States Patent (10) Patent No.: US 8,623,335 B2 Waddington (45) Date of Patent: Jan. 7, 2014 (54) SCAR AND ROSACEAAND OTHERSKIN 6,348,200 B1 2/2002 Nakajima et al. CARE TREATMENT COMPOSITION AND 6.419,962 B1 7/2002 Yokoyama et al. METHOD 6,579,543 B1 6, 2003 McClung 6,932,975 B2 8, 2005 Ishikawa et al. 2002/0106337 A1* 8, 2002 Deckers et al. ................. 424,59 (76) Inventor: Tauna Ann Waddington, Clifton Park, 2004/0076654 A1* 4/2004 Vinson et al. .. ... 424/401 NY (US) 2005/0208150 A1* 9, 2005 MittSet al. .................... 424,639 2005/0266.064 A1 12/2005 McCarthy (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 1050 days. CN 1295800 A * 5, 2001 .............. A23L 1,076 (21) Appl. No.: 12/206,833 OTHER PUBLICATIONS (22) Filed: Sep. 9, 2008 Dillardetal. “Alternative Medicine for Dummies', IDG Book World wide, Foster City, CA; 1998.* (65) Prior Publication Data RECARE 8888.08 revitalize (Clarifies, Firms & Brightens Skin). US 2009/OO68128A1 Mar 12, 2009 online 3 pages. (Product information page) retrieved on Sep. 8, s 2008. Retrieved on the internet:<URL: http://www.carebizint.com/ O O int-en/recare.html>. Related U.S. Application Data Dr. Hauschka Rhythmic Night Conditioner, online. 2 pages. (Prod (60) Provisional application No. 60/971,025, filed on Sep. uct information page) lilou-organics.com. retrieved Sep. 8, 2008. 10, 2007. Retrieved from the internet:< URL: http://www.lilou-organics.com/ scripts/prodView products.asp?idproduct=37>. (51) Int. Cl. A6 IK 8/92 (2006.01) * cited by examiner A 6LX8/97 (2006.01) A61O 1704 (2006.01) Primary Examiner — Ernst Arnold A61O 19/00 (2006.01) Assistant Examiner — Hong Yu A6 IK38/9 (2006.01) (74) Attorney, Agent, or Firm — Schmeiser, Olsen & Watts, (52) U.S. Cl. LLP USPC ............ 424/59: 424/744; 424/639: 424/85.1; 514/2; 514/559 (57) ABSTRACT (58) Field of Classification Search The present invention relates generally to composition and USPC ................ 424/59, 744, 639, 85.1: 514/2, 559 methods for topical application to skin. More particularly, it See application file for complete search history. relates to treatment of Scars and rosacea, and other aspects of skin care. A composition is disclosed having a skin toner for (56) References Cited cleansing a skin Surface, removing dead skin cells, restoring alkali balance, and shrinking skin pores; and a skin moistur U.S. PATENT DOCUMENTS izer for increasing water content in the external layers of the 6.214.352 B1 4/2001 Matsukawa skin. 6,294, 179 B1* 9/2001 Lee et al. ...................... 424/401 6,342,208 B1 1/2002 Hyldgaard et al. 19 Claims, No Drawings US 8,623,335 B2 1. 2 SCAR AND ROSACEAAND OTHERSKN that various changes and modifications may be made without CARE TREATMENT COMPOSITION AND departing from the scope of the appended claims. The scope METHOD of the present invention will in no way be limited to the number of constituting components, the materials thereof, the BACKGROUND OF THE INVENTION shapes thereof, the relative arrangement thereof, etc., and are disclosed simply as an example of an embodiment. The fea 1. Technical Field The present invention relates generally to composition and tures and advantages of the present invention are illustrated in methods for topical application to skin. More particularly, it detail in the accompanying drawings, wherein like reference relates to treatment of Scars and rosacea, and other aspects of numerals refer to like elements throughout the drawings. skin care. 10 As a preface to the detailed description, it should be noted 2. Related Art that, as used in this specification and the appended claims, the Conventional scar treatment does not adequately provide singular forms “a”, “an and “the include plural referents, for other aspects of skin care. Conventional scar treatments unless the context clearly dictates otherwise. are designed for application only to a local area containing a The composition of the present invention has been found to scar, not to skin generally. Often, the chemicals used in scar 15 have Superior and unexpected properties when applied to skin treatment products are not as desirable for use elsewhere on Such as reducing redness associated with Scars and rosacea, unscarred skin. This can result in unnecessary effort, expense, and also flattening raised Scars. The composition may include and complication when using various scar and skin care prod ingredients that serve two general functions: toning and mois ucts to treat a scar and also care for the skin generally in turizing skin. Skin toner may cleanse skin, remove dead skin Surrounding areas. cells, restore alkali balance, and shrink pores. Skin moistur The present invention overcomes these disadvantages by izer may increase water content in the external layers of the combining nourishing, natural products that benefit and pro skin. mote the health of skin generally, and are also effective for Skin toner may be formulated in various strengths includ treatment of Scars and rosacea. This removes the expense of ing skin bracers, fresheners, tonics, and astringents. A skin additional skin care products which, in turn, eliminates the 25 toner may be comprised of a single skin toning ingredient extra effort and complication associated with using the addi such as witch hazel or it may be comprised of a plurality of tional products. ingredients which may be included to serve diverse purposes Such as humectants and antiseptics. Water may also be among SUMMARY OF THE INVENTION the ingredients included in a skin toner. The present invention relates generally to compositions for 30 Skin toner may include alum, oatmeal, witch hazel, rub topical application to skin. More particularly, it relates to bing alcohol, silver nitrate, Zinc oxide, Zinc sulfate, Burows treatment of scars and rosacea, and other aspects of skin care. solution, tincture of benzoin, tannic acid, gallic acid, alumi In a first aspect, the present invention is a composition num citrate, aluminum lactate, birch extract, coffee extract, comprising: a skin toner for cleansing a skin Surface, remov evening primrose extract, grape extract, henna extract, ivy ing dead skin cells, restoring alkali balance, and shrinking 35 extract, lemon extract, aluminum salts, alfalfa extract, betula skin pores; and a skin moisturizer for increasing water content extract, citrus extract, dandelion extract, golden seal extract, in the external layers of the skin. honeysuckle extract, hops extract, ivy extract, lemon extract, In a second aspect, the present invention is a composition plantain extract, Sambucus canadensis extract, tea tree oil, comprising: a skin toner, wherein the skin toner comprises thyme extract, or any other skin toner. aloe, glycerin, vitamin E, royal jelly, and witch hazel; and a 40 Moisturizers may impart or restore moisture to skin. skin moisturizer, wherein the skin moisturizer comprises Increasing skin water content may make the skin softer and almond oil, avocado oil, coconut oil, emu oil, olive oil, and more pliable. Moisturizers may serve to mimic the action of sesame oil. normal skin secretions in maintaining Suppleness in the skin In a third aspect, the present invention is A composition and provide a barrier to evaporation. Skin moisturizer may comprising: an almond oil present up to about 8% by Volume; an aloe Vera gel present in a range of between about 25% to 45 include two general types: occlusives and humectants. Occlu about 40% by Volume; an avocado oil present in a range of sive moisturizers form a layer on the skin which reduces the between about 5% to about 15% by volume; coconut oil rate of evaporation. Humectants are nonocclusive hygro present up to about 5% by Volume; an emu oil present up to scopic Substances which retain water and make the water about 5% by volume; a vegetable glycerin present up to about available to the skin. Humectants may also function by 3% by volume; a royal jelly freeze dried in a 3.5x concentra 50 improving the lubricity of the skin. Both occlusive and tion present up to about 1% by Volume; a sesame oil present humectant moisturizers may be suitable for use in the present in a range of between about 5% to about 15% by volume; a invention. A moisturizer may be comprised of a single mois vitamin E present up to about 3% by volume; and a witch turizing ingredient Such as glycerin or it may be comprised of hazel extract present in a range of between about 25% to a plurality of ingredients which may be included to serve about 40% by volume. 55 diverse purposes Such as emollients, emulsifiers, lipids, Sur In a fourth aspect, the present invention is a method of factants, thickeners, and preservatives. Further, a moisturizer treating skin comprising: providing a skin treatment compo may have both occlusive and nonocclusive properties. Water sition including almond oil, aloe, avocado oil, coconut oil, may be among the ingredients included in a moisturizer. emu oil, glycerin, royal jelly, Sesame oil, Vitamin E, and witch Selection of the levels and types of moisturizers incorporated hazel; Supplying a skin Surface with said skin treatment com 60 in the composition may be made without adversely affecting position; and applying the skin treatment composition to the the stability of the composition or its in-use characteristics. skin. A moisturizer may include long chain C-C fatty acids, liquid water-soluble polyols, glycerin, propylene glycol, Sor DETAILED DESCRIPTION OF THE INVENTION
Load more

Recommended publications
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • SUPPLEMENTARY TABLES Compounds Pharmacology
    SUPPLEMENTARY TABLES Table S1. Pharmacology of repositioned compounds. Compounds Pharmacology Bithionol [18] • Halogenated anti-infective agent that is used against trematode and cestode infestations. • Inhibits human soluble adenylyl cyclase Tacrolimus [19] • Inhibits calcineurin phosphatase activity, thus decreases cytokine production. • Exhibits immunosuppressive activity (more potent than cyclosporine). • Prevents T-lymphocyte activation in response to antigenic or mitogenic stimulation. Floxuridine [20] • Fluorinated pyrimidine monophosphate analog of 5-fluoro-2'-deoxyuridine-5'- phosphate (FUDR-MP) with antineoplastic activity. • Inhibits thymidylate synthase, thus disrupting DNA synthesis. • Fluorouracil, the metabolized product, incorporates into RNA, which prevents the utilization of uracil in RNA synthesis. Auranofin [21] • Inhibits the activity of mitochondrial thioredoxin reductase (TrxR) by interacting with selenocysteine within the redox-active domain. • Induces mitochondrial oxidative stress, thus resulting in the induction of apoptosis. • Inhibits the JAK1/STAT3 signaling pathway, hence suppresses the expression of immune factors involved in inflammation. Drospirenone [22] • Possesses progestational and anti- mineralocorticoid activity. • Binds to the progesterone receptor, resulting in a suppression/inhibition of LH activity and ovulation (oral contraceptive). Perhexiline [23] • Binds to the mitochondrial enzyme carnitine palmitoyltransferase (CPT)-1 and CPT-2. • Shifts myocardial substrate utilization, viz., shifting from long chain fatty acids to carbohydrates via the inhibition of CPT-1 and CPT-2, thus used for the therapy in patients with ischaemia. • May cause neuropathy and hepatitis. Toremifene [24] • Selectively modulates estrogen receptors by competitively binds to the receptors, thus interferes with estrogen activity. Aspirin • Non-steroidal anti-inflammatory agent. (Acetylsalicylic • Binds to/acetylates serine residues in acid) [25] cyclooxygenases. • Decreased synthesis of prostaglandin, platelet aggregation, and inflammation.
    [Show full text]
  • ROS) in Cisplatin Chemotherapy: a Focus on Molecular Pathways and Possible Therapeutic Strategies
    molecules Review Elucidating Role of Reactive Oxygen Species (ROS) in Cisplatin Chemotherapy: A Focus on Molecular Pathways and Possible Therapeutic Strategies Sepideh Mirzaei 1, Kiavash Hushmandi 2, Amirhossein Zabolian 3, Hossein Saleki 3 , Seyed Mohammad Reza Torabi 3 , Adnan Ranjbar 3, SeyedHesam SeyedSaleh 4, Seyed Omid Sharifzadeh 3, Haroon Khan 5 , Milad Ashrafizadeh 6,7 , Ali Zarrabi 7 and Kwang-seok Ahn 8,* 1 Department of Biology, Faculty of Science, Islamic Azad University, Science and Research Branch, Tehran 1477893855, Iran; [email protected] 2 Department of Food Hygiene and Quality Control, Division of Epidemiology, Faculty of Veterinary Medicine, University of Tehran, Tehran 1417466191, Iran; [email protected] 3 Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran 1477893855, Iran; [email protected] (A.Z.); [email protected] (H.S.); [email protected] (S.M.R.T.); [email protected] (A.R.); [email protected] (S.O.S.) Citation: Mirzaei, S.; Hushmandi, K.; 4 Student Research Committee, Iran University of Medical Sciences, Tehran 1449614535, Iran; Zabolian, A.; Saleki, H.; Torabi, [email protected] 5 S.M.R.; Ranjbar, A.; SeyedSaleh, S.; Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan; [email protected] 6 Sharifzadeh, S.O.; Khan, H.; Faculty of Engineering and Natural Sciences, Sabanci University, Orta Mahalle, Üniversite Caddesi No. 27, Orhanlı, Tuzla, Istanbul 34956, Turkey; milad.ashrafi[email protected] Ashrafizadeh, M.; et al. Elucidating 7 Sabanci University Nanotechnology Research and Application Center (SUNUM), Tuzla, Role of Reactive Oxygen Species Istanbul 34956, Turkey; [email protected] (ROS) in Cisplatin Chemotherapy: A 8 Department of Science in Korean Medicine, College of Korean Medicine, Kyung Hee University, Focus on Molecular Pathways and Seoul 02447, Korea Possible Therapeutic Strategies.
    [Show full text]
  • Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan
    Volume 3 | Number 3 Article 87 2012 Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan Albert I. Wertheimer Follow this and additional works at: http://pubs.lib.umn.edu/innovations Recommended Citation Ninan B, Wertheimer AI. Withdrawing Drugs in the U.S. Versus Other Countries. Inov Pharm. 2012;3(3): Article 87. http://pubs.lib.umn.edu/innovations/vol3/iss3/6 INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing. Commentary POLICY Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan, Pharm.D.1 and Albert I Wertheimer, PhD, MBA2 1Pharmacy Intern, Rite Aid Pharmacies, Philadelphia, PA and 2Temple University School of Pharmacy, Philadelphia PA Key Words: Drug withdrawals, dangerous drugs, UN Banned Drug list Abstract Since 1979, the United Nations has maintained a list of drugs banned from sale in member countries. Interestingly, there are a number of pharmaceuticals on the market in the USA that have been banned elsewhere and similarly, there are some drug products that have been banned in the United States, but remain on the market in other countries. This report provides a look into the policies for banning drug sales internationally and the role of the United Nations in maintaining the master list for companies and countries to use for local decision guidance. Background recently updated issue is the fourteenth issue, which contains At present, one of the leading causes of death in the U.S. is data on 66 new products with updated/new information on believed to be adverse drug reactions.1-14 More than 20 22 existing products.
    [Show full text]
  • Compounds and Bulk Powders
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 1014-13 Program Prior Authorization/Notification Medication Compounds and Bulk Powders P&T Approval Date 1/2012, 02/2013, 04/2013, 07/2013, 10/2013, 11/2013, 2/2014, 4/2014, 10/2014, 4/2015, 7/2015, 4/2016, 10/2016, 10/2017, 10/2018, 10/2019, 5/2020, 1/2021 Effective Date 4/1/2021; Oxford only: 4/1/2021 1. Background: Compounded medications can provide a unique route of delivery for certain patient- specific conditions and administration requirements. Compounded medications should be produced for a single individual and not produced on a large scale. A dollar threshold may be used to identify compounds which require Notification and must meet the criteria below in order to be covered. Drugs included in the compound must be a covered product. Claims for patients under the age of 6 will process automatically for First-Lansoprazole, First-Omeprazole, and Omeprazole + Syrspend SF compounding kits. 2. Coverage Criteriaa: A. Authorization for compounds and bulk powders will be approved based on all of the following criteria (includes bulk powders requested as a single ingredient such as bulk powder formulations of cholestyramine or nystatin when the powder formulation requested is not the commercially available FDA approved product): 1. The requested drug component is a covered medication -AND- 2. The requested drug component is to be administered for an FDA-approved indication -AND- 3. If a drug included in the compound requires prior authorization and/or step therapy, all drug specific clinical criteria must also be met -AND- 4.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,911,773 B2 Kimball (45) Date of Patent: *Dec
    US00891. 1773B2 (12) United States Patent (10) Patent No.: US 8,911,773 B2 Kimball (45) Date of Patent: *Dec. 16, 2014 (54) PEELABLE POUCH FORTRANSDERMAL (56) References Cited PATCH AND METHOD FOR PACKAGING U.S. PATENT DOCUMENTS (71) Applicant: Watson Laboratories, Inc., Salt Lake 2.954,116 A 9, 1960 Maso et al. City, UT (US) 2,998,880 A 9, 1961 Ladd 3.057467 A 10, 1962 Williams 3,124,825. A 3, 1964 Iovenko (72) Inventor: Michael W. Kimball, Salt Lake City, UT 3,152,515 A 10, 1964 Land (US) 3,152,694 A 10, 1964 Nashed et al. 3,186,869 A 6, 1965 Friedman (73) Assignee: Watson Laboratories, Inc., Salt Lake 3,217,871 A 11/1965 Lee 3,403,776 A 10/1968 Denny City, UT (US) 3,478,868 A 1 1/1969 Nerenberg et al. 3,552,638 A 1/1971 Quackenbush (*) Notice: Subject to any disclaimer, the term of this 3,563,371 A 2, 1971 Heinz patent is extended or adjusted under 35 3,616,898 A 11/1971 Massie U.S.C. 154(b) by 0 days. 3,708, 106 A 1/1973 Sargent 3,847,280 A 11/1974 Poncy This patent is Subject to a terminal dis 3,913,789 A 10, 1975 Miller claimer. 3,926,311 A 12/1975 Laske 3,937,396 A 2f1976 Schneider 3,995,739 A 12/1976 Tasch et al. (21) Appl. No.: 14/090,502 4,279.344 A 7/1981 Holloway, Jr. 4.410,089 A 10, 1983 Bortolani 4,552,269 A 1 1/1985 Chang (22) Filed: Nov.
    [Show full text]
  • VIEW Open Access Novel Drugs That Target the Metabolic Reprogramming in Renal Cell Cancer Johannes C
    van der Mijn et al. Cancer & Metabolism (2016) 4:14 DOI 10.1186/s40170-016-0154-8 REVIEW Open Access Novel drugs that target the metabolic reprogramming in renal cell cancer Johannes C. van der Mijn1,2,3*, David J. Panka1, Andrew K. Geissler1, Henk. M. Verheul2 and James W. Mier1 Abstract Molecular profiling studies of tumor tissue from patients with clear cell renal cell cancer (ccRCC) have revealed extensive metabolic reprogramming in this disease. Associations were found between metabolic reprogramming, histopathologic Fuhrman grade, and overall survival of patients. Large-scale genomics, proteomics, and metabolomic analyses have been performed to identify the molecular players in this process. Genes involved in glycolysis, the pentose phosphate pathway, glutamine metabolism, and lipogenesis were found to be upregulated in renal cell cancer (RCC) specimens as compared to normal tissue. Preclinical research indicates that mutations in VHL, FBP1, and the PI3K-AKT-mTOR pathway drives aerobic glycolysis through transcriptional activation of the hypoxia-inducible factors (HIF). Mechanistic studies revealed glutamine as an important source for de novo fatty acid synthesis through reductive carboxylation. Amplification of MYC drives reductive carboxylation. In this review, we present a detailed overview of the metabolic changes in RCC in conjunction with potential novel therapeutics. We discuss preclinical studies that have investigated targeted agents that interfere with various aspects of tumor cell metabolism and emphasize their impact specifically on glycolysis, lipogenesis, and tumor growth. Furthermore, we describe a number of phase 1 and 2 clinical trials that have been conducted with these agents. Keywords: Warburg, Renal cell cancer, HIF, MYC, Glutamine Background tumor cells.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Drugs for Parasitic Infections (2013 Edition)
    The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call: 800-211-2769 Drugs for Parasitic Infections With increasing travel, immigration, use of immunosuppressive drugs and the spread of HIV, physicians anywhere may see infections caused by parasites. The table below lists first- choice and alternative drugs for most parasitic infections. The principal adverse effects of these druugs are listed on pages e24-27. The table that begins on page e28 summarizes the known pre- natal risks of antiparasitic drugs. The brand names and manufacturers of the drugs are listed on pages e30-31. ACANTHAMOEBA keratitis Drug of choice: Keratitis is typically associated with contact lens use.1 A topical biguanide, 0.02% chlorhexi- dine or polyhexamethylene biguanide (PHMB, 0.02%), either alone or combined with a diami- dine, propamidine isethionate (Brolene) or hexamidine (Desomodine), have been used suc- cessfully.2 They are administered hourly (or alternating every half hour) day and night for the first 48 hours and then continued on a reduced schedule for days to months.3 None of these drugs is commercially available or approved for use in the US, but they can be obtained from compounding pharmacies. Leiter’s Park Avenue Pharmacy, San Jose, CA (800-292-6773; www.leiterrx.com) is a compounding pharmacy that specializes in ophthalmic drugs. Expert Compounding Pharmacy, 6744 Balboa Blvd., Lake Balboa, CA 91406 (800-247-9767) and Medical Center Pharmacy, New Haven, CT (203-688-7064) are also compounding pharmacies.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • In Vitro Toxicity of Bithionol and Bithionol Sulphoxide to Neoparamoeba Spp., the Causative Agent of Amoebic Gill Disease (AGD)
    Vol. 91: 257–262, 2010 DISEASES OF AQUATIC ORGANISMS Published September 17 doi: 10.3354/dao02269 Dis Aquat Org NOTE In vitro toxicity of bithionol and bithionol sulphoxide to Neoparamoeba spp., the causative agent of amoebic gill disease (AGD) Renee L. Florent1, Joy A. Becker1, 2, Mark D. Powell1, 3,* 1Aquafin CRC, National Centre for Marine Conservation and Resource Sustainability, University of Tasmania, Locked Bag 1370 Launceston, Tasmania 7250, Australia 2Faculty of Veterinary Science, University of Sydney, 425 Werombi Road, Camden, NSW 2570, Australia 3Faculty of Biosciences and Aquaculture, Bodø University College, Postboks 1490, Bodø, N-8049, Norway ABSTRACT: The objective of the present study was to evaluate the in vitro toxicity of bithionol and bithionol sulphoxide to Neoparamoeba spp., the causative agent of amoebic gill disease (AGD). The current treatment for AGD-affected Atlantic salmon involves bathing sea-caged fish in freshwater for a minimum of 3 h, a labour-intensive and costly exercise. Previous attempts to identify alternative treatments have suggested bithionol as an alternate therapeutic, but extensive in vitro efficacy test- ing has not yet been done. In vitro toxicity to Neoparamoeba spp. was examined using amoebae iso- lated from the gill of AGD-affected Atlantic salmon and exposing the parasites to freshwater, alumina (10 mg l–1), seawater, bithionol or bithionol sulphoxide at nominal concentrations of 0.1, 0.5, 1, 5 and 10 mg l–1 in seawater. The numbers of viable amoebae were counted using the trypan blue exclusion method at 0, 24, 48 and 72 h. Both bithionol and bithionol sulphoxide demonstrated in vitro toxicity to Neoparamoeba spp.
    [Show full text]